Amgen Ordered to Pay $406M for Monopolizing Cholesterol Drug

---

Full Story

A Delaware federal jury ordered Amgen to pay $406 million to Regeneron for monopolizing the cholesterol drug market with its drug Repatha, harming sales of Regeneron’s Praluent. The ruling addresses anticompetitive practices in pharmaceuticals. It could reshape market dynamics. The case highlights tensions in drug pricing.

Amgen’s actions boosted Repatha’s sales unfairly. Regeneron’s Praluent suffered significant market losses.

MEDIA REPORTING

See how news sources on all sides are covering this story.

Left 42% | Right 17% | Center 33% | Unrated 8%

The Context

The jury found Amgen guilty of anticompetitive behavior. The $406 million penalty aims to restore fairness.

Cholesterol drugs are critical for millions of patients. Market control affects prices and access.

The U.S. has strict laws against monopolistic practices. This ruling reinforces those legal standards.

Regeneron and Amgen are major biotech competitors. Their rivalry drives innovation but also disputes.

Some support the verdict for promoting fair competition. Others warn it may deter pharmaceutical investment.

The case reflects broader concerns about drug costs. Patients seek affordable access to vital medications.